SanMedTech (01302) announces the two-year follow-up results of the Phase II and Phase III clinical studies of the IBS absorbable drug-eluting coronary stent system.

According to the Zhixin Finance APP, Xianjian Technology (01302) has announced that the IBS absorbable drug-eluting coronary stent system independently developed by the group has successfully completed the two-year follow-up of Phase II clinical research and Phase III clinical research. On October 26-27, 2025 local time in the United States, Professor Song Lei from the Fuwai Hospital of the Chinese Academy of Medical Sciences, on behalf of Academician Gao Runlin and all researchers, announced the two-year main endpoint imaging follow-up results of the IBS coronary stent Phase II clinical research and the two-year clinical endpoint follow-up results of the Phase III clinical research at the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2025).